Study type: In vitro · Status: Evidence verified by machine against declared source
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.
OncoTargets and therapy · 2025
Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Abstract only: Open source record
Product or molecular entity relationships
- Thymosin Alpha 1: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study design
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study scale
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Comparator
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Outcomes examined
Cell proliferation was assessed after treatments with scalar doses of Tα1 in tumor cMM (ie, Mel146, Mel195, Mel261, Mel514, Mel599, and Mel601), GBM (ie, LN-18, DBTRG-05MG, SiGBM56, and SiGBM71), and PM (ie, Meso4, Meso6, and Meso7) cell lines (1 µM, 10 µM, 100 µM) and in HD’s immune cell subsets (30 nM, 300 nM, 3 µM), by the WST-1 assay (Roche, Molecular Biochemicals, Mannheim, Germany).
Key findings
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.